(Q34550440)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Peggy A Scherle

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

English

0 references

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

613-625

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16862192%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc1929

27 December 2019

exact match

0 references

cites work

Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.

1 reference

Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement

21 January 2018

1 reference

Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

21 January 2018

1 reference

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice

21 January 2018

1 reference

Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

21 January 2018

1 reference

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

21 January 2018

1 reference

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

21 January 2018

1 reference

Induction of antitumor immunity by indomethacin

21 January 2018

1 reference

Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.

21 January 2018

1 reference

Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells

21 January 2018

1 reference

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine

21 January 2018

1 reference

Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.

21 January 2018

1 reference

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects

21 January 2018

1 reference

Activation of dendritic cells via inhibition of Jak2/STAT3 signaling

21 January 2018

1 reference

Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.

21 January 2018

1 reference

Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

21 January 2018

1 reference

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

21 January 2018

1 reference

Prostaglandin E2 up-regulates macrophage-derived chemokine production but suppresses IFN-inducible protein-10 production by APC.

21 January 2018

1 reference

Safeguarding patients in clinical trials with high mortality rates

21 January 2018

1 reference

Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.

21 January 2018

1 reference

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

31 March 2020

Inflammation and cancer

1 reference

Cancer immunoediting: from immunosurveillance to tumor escape

31 March 2020

1 reference

Immunosuppressive networks in the tumour environment and their therapeutic relevance

31 March 2020

1 reference

Cancer immunotherapy: moving beyond current vaccines

31 March 2020

1 reference

IDO expression by dendritic cells: tolerance and tryptophan catabolism

31 March 2020

1 reference

Prevention of allogeneic fetal rejection by tryptophan catabolism

31 March 2020

1 reference

Inhibition of T cell proliferation by macrophage tryptophan catabolism

31 March 2020

1 reference

THE role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-γin vivo

31 March 2020

1 reference

Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma

31 March 2020

1 reference

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

31 March 2020

1 reference

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

31 March 2020

1 reference

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

31 March 2020

1 reference

Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer.

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

31 March 2020

1 reference

A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation

31 March 2020

1 reference

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

31 March 2020

1 reference

The immunoregulatory role of IDO-producing human dendritic cells revisited

31 March 2020

1 reference

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase

31 March 2020

1 reference

Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells.

31 March 2020

1 reference

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

31 March 2020

1 reference

Indoleamine 2,3 dioxygenase and regulation of T cell immunity

31 March 2020

1 reference

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

31 March 2020

1 reference

1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase

31 March 2020

1 reference

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

31 March 2020

1 reference

Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

31 March 2020

1 reference

Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase

31 March 2020

1 reference

Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast

31 March 2020

1 reference

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

31 March 2020

1 reference

Regulation of immune responses by L-arginine metabolism

31 March 2020

1 reference

T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress

31 March 2020

1 reference

Polyamines and cancer: old molecules, new understanding

31 March 2020

1 reference

STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion

31 March 2020

1 reference

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

31 March 2020

1 reference

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion

31 March 2020

1 reference

Regulation of T cell receptor CD3zeta chain expression by L-arginine

31 March 2020

1 reference

Coinduction of nitric-oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide

31 March 2020

1 reference

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

31 March 2020

1 reference

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

31 March 2020

1 reference

Recognition of alpha-amino acids bearing various C=NOH functions by nitric oxide synthase and arginase involves very different structural determinants

31 March 2020

1 reference

Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response.

31 March 2020

1 reference

Classical and slow-binding inhibitors of human type II arginase

31 March 2020

1 reference

Arginases I and II: do their functions overlap?

31 March 2020

1 reference

Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study

31 March 2020

1 reference

Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer

31 March 2020

1 reference

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

31 March 2020

1 reference

Cyclooxygenase inhibitors modulate NK activities that control metastatic disease

31 March 2020

1 reference

Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice

31 March 2020

1 reference

Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer

31 March 2020

1 reference

Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer

31 March 2020

1 reference

A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation

31 March 2020

1 reference

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

31 March 2020

1 reference

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

31 March 2020

1 reference

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

31 March 2020

1 reference

Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer

31 March 2020

1 reference

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

31 March 2020

1 reference

Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial

31 March 2020

1 reference

Cardiovascular effects of selective cyclooxygenase-2 inhibitors

31 March 2020

1 reference

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor

31 March 2020

1 reference

Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor

31 March 2020

1 reference

Targeting the TGF beta signaling network in human neoplasia

31 March 2020

1 reference

Development of TGF-beta signalling inhibitors for cancer therapy

31 March 2020

1 reference

Both IL-2 and IL-4 synergize with IL-12 to induce a CTL response, a response completely blocked by TGF-beta

31 March 2020

1 reference

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance

31 March 2020

1 reference

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

31 March 2020

1 reference

Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation

31 March 2020

1 reference

Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma

31 March 2020

1 reference

TGF-beta1 regulation of dendritic cells

31 March 2020

1 reference

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

31 March 2020

1 reference

Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes

31 March 2020

1 reference

CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness

31 March 2020

1 reference

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

31 March 2020

1 reference

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

31 March 2020

1 reference

TGF-beta inhibitors for the treatment of cancer

31 March 2020

1 reference

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

31 March 2020

1 reference

The JAK/STAT signaling pathway

31 March 2020

1 reference

IL-23 promotes tumour incidence and growth

31 March 2020

1 reference

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

31 March 2020

1 reference

Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway

31 March 2020

1 reference

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

31 March 2020

1 reference

NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway

31 March 2020

1 reference

Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice

31 March 2020

1 reference

Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma

31 March 2020

1 reference

New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway.

31 March 2020

1 reference

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

31 March 2020

1 reference

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

31 March 2020

1 reference

Chemokines: agents for the immunotherapy of cancer?

31 March 2020

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

31 March 2020

1 reference

Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells

31 March 2020

1 reference

Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor

31 March 2020

1 reference

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

31 March 2020

1 reference

Cancer and the chemokine network

31 March 2020

1 reference

Immunotherapy and chemotherapy--a practical partnership

31 March 2020

1 reference

Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer

31 March 2020

1 reference

Cyclooxygenase-2 as a target for anticancer drug development

31 March 2020

1 reference

Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

31 March 2020

1 reference

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

31 March 2020

1 reference

Marrying immunotherapy with chemotherapy: why say IDO?

31 March 2020

1 reference

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

31 March 2020

1 reference

Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine

31 March 2020

1 reference

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

31 March 2020

1 reference

Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase.

31 March 2020

1 reference

The bicyclam AMD3100 story

31 March 2020

1 reference